BindingDB

null

SMILES [#6]-[#7](-[#6])-[#6]-[#6]\[#6]=[#6]-1/c2ccccc2-[#6]-[#6]-c2ccccc-12

InChI Key InChIKey=KRMDCWKBEZIMAB-UHFFFAOYSA-N

PDB links: 2 PDB IDs match this monomer.

Activity Spreadsheet -- Enzyme Inhibition Constant Data from BindingDB

Found 1 hit for monomerid = 50020712

Potassium voltage-gated channel subfamily H member 2(Homo sapiens (Human))
University of Bologna

Curated by ChEMBL

BDBM50020712(10,11-dihydro-5-(gamma-dimethylaminopropylidene)-5...)copy SMILEScopy InChI

IC50: 1.00E+4nMAssay Description:K+ channel blocking activity in human embryonic kidney cells expressing HERG Kv11.1More data for this Ligand-Target Pair

PDB MMDB Reactome pathway KEGG
UniProtKB/SwissProt
B.MOAD DrugBank antibodypedia GoogleScholar

Purchase CHEMBL DrugBank MCE
KEGG MMDB PC cid PC sid PDB Patents Similars

Details
BindingDB Entry DOI: 10.7270/Q2NC61X3PubMed

Targets 45 ▿
- Potassium voltage-gated channel subfamily H member 2 15
- 5-hydroxytryptamine receptor 6 12
- Sodium-dependent serotonin transporter 8
- Histamine H1 receptor 7
- Alpha-1A adrenergic receptor 6
- High affinity nerve growth factor receptor 6
- Sodium-dependent noradrenaline transporter 5
- Muscarinic acetylcholine receptor M2 5
- Sodium-dependent dopamine transporter 5
- 5-hydroxytryptamine receptor 2C 3
- D(2) dopamine receptor 3
- 5-hydroxytryptamine receptor 1A 3
- Norepinephrine transporter 3
- 5-hydroxytryptamine receptor 2A 3
- 5-hydroxytryptamine receptor 7 3
- Muscarinic acetylcholine receptor M5 2
- Muscarinic acetylcholine receptor M3 2
- D(1A) dopamine receptor 2
- Voltage-dependent L-type calcium channel subunit alpha-1C 2
- Muscarinic acetylcholine receptor M1 2
- Sodium channel protein type 9 subunit alpha 2
- Bile salt export pump 2
- Alpha-2A adrenergic receptor 2
- Sodium channel protein type 7 subunit alpha 1
- Solute carrier family 22 member 1 1
- Voltage-dependent L-type calcium channel subunit alpha-1C/alpha-1D/alpha-1F/alpha-1S 1
- Sodium channel protein type 2 subunit alpha 1
- Sigma non-opioid intracellular receptor 1 1
- Voltage-dependent N-type calcium channel subunit alpha-1B 1
- Histamine H3 receptor 1
- Albumin 1
- Muscarinic acetylcholine receptor M4 1
- Histamine H4 receptor 1
- Sodium channel protein type 5 subunit alpha 1
- Beta-2 adrenergic receptor 1
- ATP-binding cassette sub-family C member 3 1
- ATP-binding cassette sub-family C member 4 1
- Alpha-2C adrenergic receptor 1
- ATP-binding cassette sub-family C member 2 1
- D(3) dopamine receptor 1
- Proto-oncogene tyrosine-protein kinase receptor Ret 1
- D(1B) dopamine receptor 1
- Transporter 1
- Sodium channel protein type 1/2/3 subunit alpha 1
- Histamine H2 receptor 1
- ...
Publications 47 ▿
- Cell Mol Neurobiol 19: 467-89 (1999) 12
- J Pharmacol Exp Ther 283: 1305-22 (1997) 11
- Psychopharmacology (Berl) 114: 559-65 (1994) 7
- J Med Chem 58: 767-77 (2015) 6
- Bioorg Med Chem Lett 19: 538-42 (2008) 6
- Biochem Pharmacol 45: 2352-4 (1993) 5
- Biol Psychiatry 55: 320-2 (2004) 5
- J Med Chem 55: 6866-80 (2012) 4
- Toxicol Sci 136: 216-41 (2013) 4
- J Pharmacol Exp Ther 226: 686-700 (1983) 3
- J Med Chem 42: 3154-62 (1999) 3
- Schizophr Res 37: 107-22 (1999) 3
- Mol Pharmacol 64: 1295-308 (2003) 3
- Cardiovasc Res 91: 53-61 (2011) 3
- J Med Chem 62: 1859-1874 (2019) 2
- Br J Pharmacol 130: 692-8 (2000) 2
- Psychopharmacology (Berl) 126: 234-40 (1996) 2
- Eur J Pharmacol 340: 249-58 (1997) 2
- Mol Pharmacol 13: 454-73 (1977) 2
- Eur J Med Chem 164: 273-281 (2019) 2
- J Med Chem 59: 6329-43 (2016) 2
- Neuropharmacology 33: 275-317 (1994) 2
- J Med Chem 27: 616-27 (1984) 2
- Neuropharmacology 36: 713-20 (1997) 2
- J Biol Chem 268: 18200-4 (1993) 2
- J Appl Toxicol 32: 858-66 (2012) 2
- Mol Pharmacol 43: 320-7 (1993) 2
- Bioorg Med Chem Lett 15: 1737-41 (2005) 1
- US Patent US8629135 (2014) 1
- Mol Pharmacol 59: 427-33 (2001) 1
- Eur J Med Chem 46: 618-30 (2011) 1
- Bioorg Med Chem Lett 15: 2886-90 (2005) 1
- Neuropharmacology 32: 737-43 (1993) 1
- Bioorg Med Chem 16: 6252-60 (2008) 1
- J Med Chem 45: 3844-53 (2002) 1
- Bioorg Med Chem Lett 28: 974-978 (2018) 1
- Eur J Med Chem 44: 1926-32 (2009) 1
- Toxicol Sci 118: 485-500 (2010) 1
- J Med Chem 28: 381-8 (1985) 1
- Proc Natl Acad Sci U S A 75: 6290-4 (1978) 1
- Drug Metab Dispos 39: 312-21 (2011) 1
- J Med Chem 51: 5932-42 (2008) 1
- J Neurochem 66: 47-56 (1996) 1
- J Pharm Pharmacol 38: 374-9 (1986) 1
- Bioorg Med Chem Lett 13: 2773-5 (2003) 1
- Mol Pharmacol 44: 229-36 (1993) 1
- Brain Res 304: 1-7 (1984) 1
Institutions 37 ▿
- [TBA] 19
- [Emory University] 16
- [Mayo Clinic Jacksonville] 9
- [Mayo Foundation, Southmead Hospital, Johann Wolfgang Goethe Universit£t] 6
- [Mayo Foundation, Southmead Hospital, Johann Wolfgang Goethe Universit£t] 6
- [Mayo Foundation, Southmead Hospital, Johann Wolfgang Goethe Universit£t] 6
- [National Institute of Neurological Disorders and Stroke, GlaxoSmithKline, AstraZeneca, Amgen Inc] 4
- [National Institute of Neurological Disorders and Stroke, GlaxoSmithKline, AstraZeneca, Amgen Inc] 4
- [National Institute of Neurological Disorders and Stroke, GlaxoSmithKline, AstraZeneca, Amgen Inc] 4
- [National Institute of Neurological Disorders and Stroke, GlaxoSmithKline, AstraZeneca, Amgen Inc] 4
- [Lilly Research Laboratories, Universidad de Valencia, University of Oxford, Pfizer Inc.,] 3
- [Lilly Research Laboratories, Universidad de Valencia, University of Oxford, Pfizer Inc.,] 3
- [Lilly Research Laboratories, Universidad de Valencia, University of Oxford, Pfizer Inc.,] 3
- [Lilly Research Laboratories, Universidad de Valencia, University of Oxford, Pfizer Inc.,] 3
- [Friedrich-Schiller-University Jena, University of Alberta, F. Hoffmann-La Roche Ltd., Emory University School of Medicine, Jagiellonian University, University of Kentucky, University of Turku, East China Normal University] 2
- [Friedrich-Schiller-University Jena, University of Alberta, F. Hoffmann-La Roche Ltd., Emory University School of Medicine, Jagiellonian University, University of Kentucky, University of Turku, East China Normal University] 2
- [Friedrich-Schiller-University Jena, University of Alberta, F. Hoffmann-La Roche Ltd., Emory University School of Medicine, Jagiellonian University, University of Kentucky, University of Turku, East China Normal University] 2
- [Friedrich-Schiller-University Jena, University of Alberta, F. Hoffmann-La Roche Ltd., Emory University School of Medicine, Jagiellonian University, University of Kentucky, University of Turku, East China Normal University] 2
- [Friedrich-Schiller-University Jena, University of Alberta, F. Hoffmann-La Roche Ltd., Emory University School of Medicine, Jagiellonian University, University of Kentucky, University of Turku, East China Normal University] 2
- [Friedrich-Schiller-University Jena, University of Alberta, F. Hoffmann-La Roche Ltd., Emory University School of Medicine, Jagiellonian University, University of Kentucky, University of Turku, East China Normal University] 2
- [Friedrich-Schiller-University Jena, University of Alberta, F. Hoffmann-La Roche Ltd., Emory University School of Medicine, Jagiellonian University, University of Kentucky, University of Turku, East China Normal University] 2
- [Friedrich-Schiller-University Jena, University of Alberta, F. Hoffmann-La Roche Ltd., Emory University School of Medicine, Jagiellonian University, University of Kentucky, University of Turku, East China Normal University] 2
- [Beijing University of Technology, Uppsala University, Hoffmann-La Roche, CASMedChem Laboratory, Reverse proteomics research institute, CNRS, Queen's University at Kingston, The Centre for Addiction and Mental Health, University of Washington, Gedeon Richter Ltd, Johnson& Johnson Pharmaceutical Research& Development, TCG Lifesciences Ltd., University of Bologna, Boots Pharmaceuticals, Amgen Inc.] 1
- [Beijing University of Technology, Uppsala University, Hoffmann-La Roche, CASMedChem Laboratory, Reverse proteomics research institute, CNRS, Queen's University at Kingston, The Centre for Addiction and Mental Health, University of Washington, Gedeon Richter Ltd, Johnson& Johnson Pharmaceutical Research& Development, TCG Lifesciences Ltd., University of Bologna, Boots Pharmaceuticals, Amgen Inc.] 1
- [Beijing University of Technology, Uppsala University, Hoffmann-La Roche, CASMedChem Laboratory, Reverse proteomics research institute, CNRS, Queen's University at Kingston, The Centre for Addiction and Mental Health, University of Washington, Gedeon Richter Ltd, Johnson& Johnson Pharmaceutical Research& Development, TCG Lifesciences Ltd., University of Bologna, Boots Pharmaceuticals, Amgen Inc.] 1
- [Beijing University of Technology, Uppsala University, Hoffmann-La Roche, CASMedChem Laboratory, Reverse proteomics research institute, CNRS, Queen's University at Kingston, The Centre for Addiction and Mental Health, University of Washington, Gedeon Richter Ltd, Johnson& Johnson Pharmaceutical Research& Development, TCG Lifesciences Ltd., University of Bologna, Boots Pharmaceuticals, Amgen Inc.] 1
- [Beijing University of Technology, Uppsala University, Hoffmann-La Roche, CASMedChem Laboratory, Reverse proteomics research institute, CNRS, Queen's University at Kingston, The Centre for Addiction and Mental Health, University of Washington, Gedeon Richter Ltd, Johnson& Johnson Pharmaceutical Research& Development, TCG Lifesciences Ltd., University of Bologna, Boots Pharmaceuticals, Amgen Inc.] 1
- [Beijing University of Technology, Uppsala University, Hoffmann-La Roche, CASMedChem Laboratory, Reverse proteomics research institute, CNRS, Queen's University at Kingston, The Centre for Addiction and Mental Health, University of Washington, Gedeon Richter Ltd, Johnson& Johnson Pharmaceutical Research& Development, TCG Lifesciences Ltd., University of Bologna, Boots Pharmaceuticals, Amgen Inc.] 1
- [Beijing University of Technology, Uppsala University, Hoffmann-La Roche, CASMedChem Laboratory, Reverse proteomics research institute, CNRS, Queen's University at Kingston, The Centre for Addiction and Mental Health, University of Washington, Gedeon Richter Ltd, Johnson& Johnson Pharmaceutical Research& Development, TCG Lifesciences Ltd., University of Bologna, Boots Pharmaceuticals, Amgen Inc.] 1
- [Beijing University of Technology, Uppsala University, Hoffmann-La Roche, CASMedChem Laboratory, Reverse proteomics research institute, CNRS, Queen's University at Kingston, The Centre for Addiction and Mental Health, University of Washington, Gedeon Richter Ltd, Johnson& Johnson Pharmaceutical Research& Development, TCG Lifesciences Ltd., University of Bologna, Boots Pharmaceuticals, Amgen Inc.] 1
- [Beijing University of Technology, Uppsala University, Hoffmann-La Roche, CASMedChem Laboratory, Reverse proteomics research institute, CNRS, Queen's University at Kingston, The Centre for Addiction and Mental Health, University of Washington, Gedeon Richter Ltd, Johnson& Johnson Pharmaceutical Research& Development, TCG Lifesciences Ltd., University of Bologna, Boots Pharmaceuticals, Amgen Inc.] 1
- [Beijing University of Technology, Uppsala University, Hoffmann-La Roche, CASMedChem Laboratory, Reverse proteomics research institute, CNRS, Queen's University at Kingston, The Centre for Addiction and Mental Health, University of Washington, Gedeon Richter Ltd, Johnson& Johnson Pharmaceutical Research& Development, TCG Lifesciences Ltd., University of Bologna, Boots Pharmaceuticals, Amgen Inc.] 1
- [Beijing University of Technology, Uppsala University, Hoffmann-La Roche, CASMedChem Laboratory, Reverse proteomics research institute, CNRS, Queen's University at Kingston, The Centre for Addiction and Mental Health, University of Washington, Gedeon Richter Ltd, Johnson& Johnson Pharmaceutical Research& Development, TCG Lifesciences Ltd., University of Bologna, Boots Pharmaceuticals, Amgen Inc.] 1
- [Beijing University of Technology, Uppsala University, Hoffmann-La Roche, CASMedChem Laboratory, Reverse proteomics research institute, CNRS, Queen's University at Kingston, The Centre for Addiction and Mental Health, University of Washington, Gedeon Richter Ltd, Johnson& Johnson Pharmaceutical Research& Development, TCG Lifesciences Ltd., University of Bologna, Boots Pharmaceuticals, Amgen Inc.] 1
- [Beijing University of Technology, Uppsala University, Hoffmann-La Roche, CASMedChem Laboratory, Reverse proteomics research institute, CNRS, Queen's University at Kingston, The Centre for Addiction and Mental Health, University of Washington, Gedeon Richter Ltd, Johnson& Johnson Pharmaceutical Research& Development, TCG Lifesciences Ltd., University of Bologna, Boots Pharmaceuticals, Amgen Inc.] 1
- [Beijing University of Technology, Uppsala University, Hoffmann-La Roche, CASMedChem Laboratory, Reverse proteomics research institute, CNRS, Queen's University at Kingston, The Centre for Addiction and Mental Health, University of Washington, Gedeon Richter Ltd, Johnson& Johnson Pharmaceutical Research& Development, TCG Lifesciences Ltd., University of Bologna, Boots Pharmaceuticals, Amgen Inc.] 1
- [Beijing University of Technology, Uppsala University, Hoffmann-La Roche, CASMedChem Laboratory, Reverse proteomics research institute, CNRS, Queen's University at Kingston, The Centre for Addiction and Mental Health, University of Washington, Gedeon Richter Ltd, Johnson& Johnson Pharmaceutical Research& Development, TCG Lifesciences Ltd., University of Bologna, Boots Pharmaceuticals, Amgen Inc.] 1
Affinity: 0.020 to 2.2E+6 nM▿
- Ki 81
- IC50 38
- Kd 5
- EC50 1
- Affinity ≤ nM
Xtal structures: 0
Docked structures: 0
Catalog Cmpds: 1